Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.01%||177.18||0.7%||$1153.99m|
|LLY||Eli Lilly & Co.||-0.05%||371.79||1.1%||$1049.81m|
|MRK||Merck & Co., Inc.||0.70%||110.86||0.7%||$1003.98m|
|BMY||Bristol-Myers Squibb Co.||0.00%||79.93||1.1%||$735.65m|
|HZNP||Horizon Therapeutics Plc||0.63%||96.91||5.4%||$294.05m|
|IDXX||IDEXX Laboratories, Inc.||2.01%||428.54||3.9%||$192.93m|
|ALNY||Alnylam Pharmaceuticals, Inc.||2.89%||238.01||8.0%||$173.86m|
|NVO||Novo Nordisk A/S||2.08%||127.84||0.1%||$148.14m|
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy. The company was founded on June 5, 1987 and is headquartered in Princeton, NJ.